ANAB
USDAnaptysBio Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$23.650
Kõrge
$24.130
Madal
$23.508
Maht
0.34M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
697.8M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.64M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
HC Wainwright & Co. Upgrades AnaptysBio to Buy, Raises Price Target to $38
HC Wainwright & Co. analyst Emily Bodnar upgrades AnaptysBio from Neutral to Buy and raises the price target from $22 to $38.
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month blinded treatment periodFavorable safety and tolerability, particularly when compared to
Guggenheim Maintains Buy on AnaptysBio, Raises Price Target to $90
Guggenheim analyst Yatin Suneja maintains AnaptysBio with a Buy and raises the price target from $54 to $90.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.